Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Time to Buy?

Shares of Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up prior to trading on Friday . The stock had previously closed at $17.49, but opened at $18.68. Daiichi Sankyo shares last traded at $18.19, with a volume of 59,723 shares traded.

Analysts Set New Price Targets

Several brokerages have recently weighed in on DSNKY. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Performance

The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96. The stock has a market capitalization of $33.81 billion, a PE ratio of 21.10, a P/E/G ratio of 2.41 and a beta of -0.11. The stock has a 50 day moving average of $17.40 and a two-hundred day moving average of $17.29.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. Research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.